Clinical Trials /

Lenvatinib and Pembrolizumab in DTC

NCT02973997

Description:

This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Related Conditions:
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Oncocytic Follicular Carcinoma
  • Thyroid Gland Papillary Carcinoma
  • Well-Differentiated Thyroid Gland Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
  • Official Title: Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

Clinical Trial IDs

  • ORG STUDY ID: ACCRU-ITOG-1504
  • SECONDARY ID: NCI-2016-01752
  • SECONDARY ID: ACCRU-ITOG-1504
  • SECONDARY ID: P30CA015083
  • NCT ID: NCT02973997

Conditions

  • Columnar Cell Variant Thyroid Gland Papillary Carcinoma
  • Follicular Variant Thyroid Gland Papillary Carcinoma
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Recurrent Thyroid Gland Carcinoma
  • Stage III Differentiated Thyroid Gland Carcinoma
  • Stage III Thyroid Gland Follicular Carcinoma
  • Stage III Thyroid Gland Papillary Carcinoma
  • Stage IV Thyroid Gland Follicular Carcinoma
  • Stage IV Thyroid Gland Papillary Carcinoma
  • Stage IVA Differentiated Thyroid Gland Carcinoma
  • Stage IVA Thyroid Gland Follicular Carcinoma
  • Stage IVA Thyroid Gland Papillary Carcinoma
  • Stage IVB Differentiated Thyroid Gland Carcinoma
  • Stage IVB Thyroid Gland Follicular Carcinoma
  • Stage IVB Thyroid Gland Papillary Carcinoma
  • Stage IVC Differentiated Thyroid Gland Carcinoma
  • Stage IVC Thyroid Gland Follicular Carcinoma
  • Stage IVC Thyroid Gland Papillary Carcinoma
  • Tall Cell Variant Thyroid Gland Papillary Carcinoma
  • Thyroid Gland Oncocytic Follicular Carcinoma

Interventions

DrugSynonymsArms
LenvatinibE7080, ER-203492-00, Multi-Kinase Inhibitor E7080Treatment (lenvatinib, pembrolizumab)
PembrolizumabKeytruda, Lambrolizumab, MK-3475, SCH 900475Treatment (lenvatinib, pembrolizumab)

Purpose

This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and kinase inhibitors, such as lenvatinib, may interfere with the ability of tumor cells to grow and spread.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To investigate the clinical efficacy, as indicated by the rate of complete response (CR)
      per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, of combination therapy with
      pembrolizumab and lenvatinib in lenvatinib-naive patients with progressive
      radioiodine-refractory differentiated thyroid cancers (DTC). (Cohort 1) II. To determine the
      overall response rate (ORR) by the addition of pembrolizumab to patients with
      radioiodine-refractory DTC who have progressive disease on lenvatinib alone. (Cohort 2)

      SECONDARY OBJECTIVES:

      I. To determine the safety profile and toxicity of combination therapy with pembrolizumab
      and lenvatinib in patients with progressive DTC. (Cohort 1 and cohort 2) II. To determine
      progression-free survival (PFS) and overall survival (OS). (Cohort 1 and cohort 2)

      TERTIARY OBJECTIVES:

      I. To correlate tumor response (RECIST 1.1) with pretreatment frequency of CD8+ T cells in
      the primary and/or metastatic tumor. (Cohort 1 and cohort 2) II. To correlate tumor response
      (RECIST 1.1) with pretreatment PD-L1 and PD-L2 levels in the primary and/or metastatic
      tumor. (Cohort 1 and cohort 2) III. To correlate tumor response (RECIST 1.1) with
      pretreatment frequency of lymphocytes expressing CD3, CD4, PD-1, FoxP3, or CD20, and of
      CD163+ macrophages. (Cohort 1 and cohort 2) IV. To correlate tumor response (RECIST 1.1)
      with the phenotype and frequency of key leukocyte subsets (i.e., PD-1+ T cells, regulatory T
      cells [Tregs], myeloid subsets) in the peripheral blood before, at 6 and 18 weeks on
      therapy, and at 54 weeks (study completion), progressive disease (PD), or study withdrawal.
      (Cohort 1) V. To correlate tumor response (RECIST 1.1) with PD-1+ T cell functional
      capacity. (Cohort 1) VI. To correlate tumor response (RECIST 1.1) with serum
      anti-thyroglobulin antibody levels assessed before, and at 18 weeks on therapy. (Cohort 1
      and 2) VII. To correlate tumor response (RECIST 1.1) with tumor mutation status. (Cohort 1)
      VIII. To broadly investigate mechanisms of response and resistance to combination therapy,
      gene expression profiles will be generated from frozen biopsies for analysis by ribonucleic
      acid-sequencing (RNA-Seq). (Cohort 1)

      OUTLINE:

      Patients receive lenvatinib orally (PO) once daily (QD) on days 1-21 and pembrolizumab
      intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 19
      courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for up to 3
      years.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (lenvatinib, pembrolizumab)ExperimentalPatients receive lenvatinib mesylate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 courses in the absence of disease progression or unacceptable toxicity.
  • Lenvatinib

Eligibility Criteria

        Inclusion Criteria:

          -  Locally recurrent and unresectable and/or distant metastatic differentiated thyroid
             cancer (DTC), histologically or cytologically confirmed; the diagnosis of DTC
             includes the following subtypes: papillary thyroid cancer (PTC) (including but not
             limited to variants such as follicular variant, tall cell, columnar cell, Hurthle
             cell variant of papillary carcinoma, and poorly differentiated), follicular thyroid
             cancer (FTC), including insular variant, Hurthle cell carcinoma and poorly
             differentiated thyroid cancer

          -  Measurable disease meeting the following criteria:

               -  At least 1 lesion of >= 1.0 cm in the longest diameter for a non-lymph node or
                  >= 1.5 cm in the short-axis diameter for a lymph node which is serially
                  measurable according to RECIST 1.1 using computerized tomography/magnetic
                  resonance imaging (CT/MRI); if there is only one target lesion and it is a
                  non-lymph node, it should have a longest diameter of >= 1.5 cm

               -  Lesions that have had external beam radiotherapy (EBRT) or loco-regional
                  therapies such as radiofrequency (RF) ablation must show evidence of progressive
                  disease based on RECIST 1.1 to be deemed a target lesion

          -  For cohort 1 only: evidence of disease progression =< 14 months prior to registration
             according to RECIST 1.1, as confirmed by the site study principal investigator (PI)

          -  For cohort 2 only: progressive disease (PD) on lenvatinib per RECIST 1.1 =< 30 days
             prior to registration, as confirmed by the site study PI

          -  Radioiodine (RAI)-resistant disease as defined by one or more of the following
             criteria:

               -  One or more measurable lesions that do not demonstrate RAI uptake

               -  One or more measurable lesions progressive by RECIST 1.1 =< 14 months of prior
                  RAI therapy

               -  One or more measurable lesions present after cumulative RAI dose of >= 600 mCi

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Absolute neutrophil count (ANC) >= 1,500 /mcL

          -  Platelets >= 100,000 / mcL

          -  Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin
             dependency (=< 7 days prior to registration)

          -  Serum creatinine =< 1.5 X upper limit of normal (ULN) OR Measured or calculated
             creatinine clearance (glomerular filtration rate [GFR] can also be used in place of
             creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine
             levels > 1.5 X institutional ULN

          -  Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total
             bilirubin levels > 1.5 ULN

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5
             X ULN OR =< 5 X ULN for subjects with liver metastases

          -  Albumin >= 2.5 mg/dL

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin
             time (PTT) is within therapeutic range of intended use of anticoagulants

          -  Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving
             anticoagulant therapy as long as PT or PTT is within therapeutic range of intended
             use of anticoagulants

          -  Adequately controlled blood pressure with or without antihypertensive medications
             defined as BP < 150/90 mmHg at screening

          -  Negative pregnancy test done =< 7 days prior to registration, for women of
             childbearing potential only

          -  Ability to complete patient medication and blood pressure diaries by themselves or
             with assistance

          -  Willing and able to provide informed written consent

          -  Willing to return to enrolling institution for follow-up (during the active
             monitoring phase of the study)

               -  Note: during the active monitoring phase of a study (i.e., active treatment and
                  observation), participants must be willing to return to the consenting
                  institution for follow-up

          -  Willing to provide tissue and blood samples for correlative research purposes

        Exclusion Criteria:

          -  Cohort 1 only: prior treatment with previous VEGFR active multikinase inhibitor

          -  Cohort 2 only: discontinued lenvatinib due to toxicity

          -  Pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment

          -  Female subjects of childbearing potential: unwilling or unable to use 2 methods of
             birth control or be surgically sterile, or abstain from heterosexual activity for the
             course of the study through 120 days after the last dose of study medication; NOTE:
             subjects of childbearing potential are those who have not been surgically sterilized
             or have not been free from menses for > 1 year

          -  Male subjects: unwilling or unable to use an adequate method of contraception
             starting with the first dose of study therapy through 120 days after the last dose of
             study therapy

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the
             judgment of the investigator, would make the patient inappropriate for entry into
             this study or interfere significantly with the proper assessment of safety and
             toxicity of the prescribed regimens

          -  Immunocompromised patients and patients known to be human immunodeficiency virus
             (HIV) positive (HIV 1/2 antibodies) and currently receiving antiretroviral therapy

          -  Currently participating and receiving study therapy or has participated in a study of
             an investigational agent and received study therapy within 4 weeks prior to
             registration

          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
             form of immunosuppressive therapy =< 7 days prior to the first dose of trial
             treatment

          -  Known history of active TB (Bacillus tuberculosis)

          -  Hypersensitivity to pembrolizumab or any of its excipients

          -  Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration or who
             has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents
             administered >= 4 weeks prior to registration

          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
             weeks prior to study day 1 (except lenvatinib for patients in cohort 2) or who has
             not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a
             previously administered agent

               -  NOTE:

                    -  Subjects with =< grade 2 neuropathy are an exception to this criterion and
                       may qualify for the study

                    -  If subject received major surgery, they must have recovered adequately from
                       the toxicity and/or complications from the intervention prior to
                       registration, as deemed by treating investigator or site PI

          -  Known additional malignancy that is progressing or requires active treatment;
             exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer

          -  Known active central nervous system (CNS) metastases and/or carcinomatous meningitis;
             NOTE: subjects with previously treated brain metastases may participate provided they
             are stable (without evidence of progression by imaging for at least four weeks prior
             to the first dose of trial treatment and any neurologic symptoms have returned to
             baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for >= 7 days prior to trial treatment; this exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs); NOTE: replacement therapy (eg., thyroxine, insulin, or physiologic
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
             not considered a form of systemic treatment

          -  Known history of, or any evidence of active, non-infectious pneumonitis that required
             steroids

          -  Active infection requiring systemic therapy

          -  History or current evidence of any condition, therapy, or laboratory abnormality that
             might confound the results of the trial, interfere with the subject's participation
             for the full duration of the trial, or is not in the best interest of the subject to
             participate, in the opinion of the treating investigator

          -  Known psychiatric or substance abuse disorders that would interfere with cooperation
             with the requirements of the trial

          -  Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

          -  Known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or
             hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is
             detected)

          -  Received a live vaccine =< 30 days of planned start of study therapy; NOTE: seasonal
             influenza vaccines for injection are generally inactivated flu vaccines and are
             allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated
             vaccines, and are not allowed

          -  Proteinuria > 1+ on dipstick urinalysis; patients with > 1+ proteinuria on dipstick
             urinalysis will undergo 24-hour urine collection for quantitative assessment; NOTE:
             patients with > 1 g/24 hours will be ineligible

          -  Clinically significant gastrointestinal malabsorption syndrome

          -  New York Heart Association congestive heart failure of grade II or above, unstable
             angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia
             associated with significant cardiovascular impairment within the past 6 months;
             ejection fraction (EF) by multi-gated acquisition (MUGA) or echo should not be less
             than the institutional lower limit of normal

          -  Corrected QT (QTc) prolongation > 480 msec, as calculated by either the Bazett or
             Fridericia formula, as per institutional standard

          -  Active hemoptysis (bright red blood > 1 teaspoon on more than one occasion) =< 3
             weeks prior to registration

          -  Cohort 2 only: more than one prior treatment with VEGFR active multikinase inhibitor
             prior to original start of lenvatinib
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Confirmed response rate assessed by RECIST 1.1 (Cohort 2)
Time Frame:Up to 3 years
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
Time Frame:Up to 3 years
Safety Issue:
Description:All patients that have initiated treatment will be considered evaluable for assessing adverse events. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns. Only the grade 2+ adverse events will be assessed, regardless of relationship to the study treatment.
Measure:OS
Time Frame:From registration to death due to any cause, assessed up to 3 years
Safety Issue:
Description:The distribution of survival time will be estimated using the method of Kaplan-Meier.
Measure:PFS
Time Frame:From registration to the first of either death due to any cause or progression, assessed up to 3 years
Safety Issue:
Description:The distribution of PFS will be estimated using the method of Kaplan-Meier.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Academic and Community Cancer Research United

Last Updated

January 24, 2017